3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
6
Breast
2
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Head and Neck Neoplasms
7
Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Hypoparathyroidism
2
Carcinoma, Squamous Cell
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Diseases
1
Recurrence
1
Rectal Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Neovascularization, Pathologic
1
Melanoma
1
Margins of Excision
1
Lymphedema
1
Head and Neck Carcinoma
1
Graves Disease
1
Goiter
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Adenoma
1
Interventions
pembrolizumab
73
Nivolumab
27
atezolizumab
15
Docetaxel
10
Cyclophosphamide
10
cemiplimab
9
Ipilimumab
9
Paclitaxel
8
Interleukin-2
8
Biopsy
7
fludarabine
6
durvalumab
6
avelumab
6
Taxes
6
Specimen Handling
6
epacadostat
5
Magnetic Resonance Spectroscopy
5
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Drug Therapy
5
Cisplatin
5
Carboplatin
5
spartalizumab
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
Cetuximab
4
utomilumab
3
trametinib
3
poly ICLC
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Indocyanine Green
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled